Correction of Myopia Evaluation Trial 2

NCT ID: NCT00320593

Last Updated: 2016-07-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-04-30

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine if progressive addition lenses (PALs) versus single vision lenses (SVLs) slow the progression of low myopia in children with poor accommodative responses (i.e., large accommodative lags) and near esophoria.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Myopia is a significant public health problem that affects at least 34% of children in the United States and a much higher percentage in Asia. It is a predisposing factor for retinal detachment, myopic retinopathy, and glaucoma, thus contributing to loss of vision and blindness. As might be expected for such a prevalent condition, treatment costs are high. If interventions to retard myopia progression are successful, sight-threatening complications might be avoided and costs should be reduced.

The study has been designed as a simple trial that, other than the type of lenses being determined through the randomization process and the addition of accommodation testing using an autorefractor, largely approximates standard clinical practice.

Screening consists of non-cycloplegic procedures of subjective refraction, testing of oculomotor alignment, and testing of accommodative response using the Grand Seiko autorefractor.

Patients who appear to be eligible for the randomized trial will be tested with their eyes dilated to determine whether refractive error in each eye is within the eligibility range for the randomized trial. Patients will be randomized to either progressive addition lenses (PALs) with a +2.00 D addition or to single vision lenses (SVLs). Children will have three years of follow up, with visits every 6 months.

The primary outcome visit is timed 3 years from randomization, with the primary analysis being a comparison of the average change from baseline to 3 years in amount of myopia between children in the single-vision lens group and the children in the progressive-addition lens group. The primary outcome is change in spherical equivalent refractive error (SER) in diopters (D) as measured by cycloplegic autorefraction.

A separate ancillary study nested within the screening process will collect data on two additional methods of measuring accommodation, Monocular Estimate Method (MEM) retinoscopy and Nott retinoscopy. The aim of the ancillary study to help determine whether a simple, effective measure exists that can be easily used by clinicians to identify children with reduced accommodative response who, if they have low myopia and esophoria, might benefit from the treatment with PALs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Progressive addition lenses (PALs)

Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition

Group Type ACTIVE_COMPARATOR

Progressive Addition Lenses (PALs)

Intervention Type DEVICE

Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition

Single vision lenses (SVLs)

Single vision lenses

Group Type ACTIVE_COMPARATOR

Single Vision Lenses (SVLs)

Intervention Type DEVICE

Single vision lenses

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Progressive Addition Lenses (PALs)

Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition

Intervention Type DEVICE

Single Vision Lenses (SVLs)

Single vision lenses

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Refractive error determined by cycloplegic autorefraction which meets all of the following:

1. Spherical equivalent: -0.50 to -3.00 D in both eyes
2. Astigmatism \<= 1.5 D in both eyes
3. Anisometropia \<= 1.00 D difference between eyes in spherical equivalent
* Visual acuity is at least 20/20 with best subjective refraction in both eyes
* Accommodative response at near (33 cm) is less than 2.0D by non-cycloplegic autorefraction
* Near esophoria (\>= 2.0 PD) present by alternate prism and cover test (APCT) at near using best refractive correction determined from non-cycloplegic subjective refraction

Exclusion Criteria

* Strabismus present by cover-uncover test at far, near, and/or near with +2.00D over best subjective refraction
* Current or prior use of PALs, bifocals, or contact lenses in either eye (prior or current use of SVLs is allowed)
Minimum Eligible Age

8 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Eye Institute (NEI)

NIH

Sponsor Role collaborator

Jaeb Center for Health Research

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jane E Gwiazda, Ph.D.

Role: STUDY_CHAIR

New England College of Optometry

Wendy L Marsh-Tootle

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham School of Optometry

Ruth E Manny

Role: PRINCIPAL_INVESTIGATOR

University of Houston College of Optometry

Erik M Weissberg

Role: PRINCIPAL_INVESTIGATOR

New England College of Optometry

David I Silbert

Role: PRINCIPAL_INVESTIGATOR

Family Eye Group

Don W Lyon

Role: PRINCIPAL_INVESTIGATOR

Indiana University

Mitchell M Scheiman

Role: PRINCIPAL_INVESTIGATOR

Pennsylvania College of Optometry

Marjean T Kulp

Role: PRINCIPAL_INVESTIGATOR

Ohio State University

Susan A Cotter

Role: PRINCIPAL_INVESTIGATOR

Southern California College of Optometry at Marshall B. Ketchum University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama- Birmingham, School of Optometry

Birmingham, Alabama, United States

Site Status

Southern California College of Optometry

Fullerton, California, United States

Site Status

Indiana School of Optometry

Bloomington, Indiana, United States

Site Status

New England College of Optometry

Boston, Massachusetts, United States

Site Status

Ohio State University College of Optometry

Columbus, Ohio, United States

Site Status

Family Eye Group

Lancaster, Pennsylvania, United States

Site Status

Pennsylvania College of Optometry

Philadelphia, Pennsylvania, United States

Site Status

University of Houston College of Optometry

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group; Manny RE, Chandler DL, Scheiman MM, Gwiazda JE, Cotter SA, Everett DF, Holmes JM, Hyman LG, Kulp MT, Lyon DW, Marsh-Tootle W, Matta N, Melia BM, Norton TT, Repka MX, Silbert DI, Weissberg EM. Accommodative lag by autorefraction and two dynamic retinoscopy methods. Optom Vis Sci. 2009 Mar;86(3):233-43. doi: 10.1097/OPX.0b013e318197180c.

Reference Type RESULT
PMID: 19214130 (View on PubMed)

Correction of Myopia Evaluation Trial 2 Study Group for the Pediatric Eye Disease Investigator Group. Progressive-addition lenses versus single-vision lenses for slowing progression of myopia in children with high accommodative lag and near esophoria. Invest Ophthalmol Vis Sci. 2011 Apr 25;52(5):2749-57. doi: 10.1167/iovs.10-6631.

Reference Type RESULT
PMID: 21282579 (View on PubMed)

Lawrenson JG, Shah R, Huntjens B, Downie LE, Virgili G, Dhakal R, Verkicharla PK, Li D, Mavi S, Kernohan A, Li T, Walline JJ. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Feb 16;2(2):CD014758. doi: 10.1002/14651858.CD014758.pub2.

Reference Type DERIVED
PMID: 36809645 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2U10EY011751

Identifier Type: NIH

Identifier Source: secondary_id

View Link

5U10EY011751

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NEI-123

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Novel Lenses for Myopia Progression Trial
NCT06563700 ACTIVE_NOT_RECRUITING NA
Control of Myopia Using Novel Spectacle Lens Designs
NCT03623074 ACTIVE_NOT_RECRUITING NA
Early Intervention for Premyopic Children
NCT06200194 ACTIVE_NOT_RECRUITING PHASE2